Expressed by over 68-72% of African Americans (with >95% in West and Central Africa) and millions worldwide, the Fy(a-b-) phenotype is an evolutionary genetic variation—not an illness. We provide clarity for patients, diagnostic stewardship for clinicians, and translational data for biopharma.
African Americans (Reich et al., PLoS Genet 2009; >95% in West Africa)
× 10⁹/L reference range; ~10% have DANC < 1.5 (JAMA 2023)
Resting ANC below conventional limits (Blood Advances 2023)
ACKR1 testing can help avoid unnecessary invasive evaluation (Van Driest et al., 2021)
Understanding the molecular genetics, evolutionary history, and modern medical implications of the Fy(a-b-) phenotype.
Duffy null is caused by a single point mutation (rs2814778 / -46T>C) in the erythroid promoter region of the ACKR1 gene on Chromosome 1. This mutation specifically abolishes GATA-1 transcription factor binding, silencing Duffy protein expression on erythrocytes while leaving endothelial cell expression fully intact.
The Duffy glycoprotein is the primary erythrocyte invasion receptor for Plasmodium vivax malaria. The -46T>C mutation spread rapidly across Central and West Africa due to positive natural selection, conferring profound evolutionary protection against vivax malaria.
In modern clinical medicine, lack of clinical awareness leads to two major disparities: healthy individuals undergoing painful, unnecessary bone marrow biopsies for low white blood cell counts (DANC), and cancer patients facing inappropriate chemotherapy delays due to conventional commercial lab reference ranges.
Access tailored clinical workflows, patient guidance, or clinical trials and translational datasets.
Plain-language explanations of DANC, debunking infection myths, modern malaria facts, and our free printable Emergency Medical Wallet Card.
Evidence-based guidelines aligned with the American Society of Hematology (ASH), point-of-care ANC risk calculator, and chemo dose preservation protocols.
Live ClinicalTrials.gov study tracking, recent 2026 PubMed literature, erythrocyte ACKR1 chemokine sink biology, and clinical cohort inquiries.
DANC (Duffy-Null Associated Neutrophil Count) describes the lower baseline neutrophil count associated with Duffy-null status. "Benign ethnic neutropenia" (BEN) is the older clinical term that is increasingly being retired because the phenotype is genetic rather than defined by ethnicity. Duffy-null itself is the red blood cell blood-group phenotype, while DANC describes its specific hematological manifestation.
It is present in approximately 68% to 72% of African Americans and upwards of 95% to 100% of indigenous populations in West and Central Africa. It is also found in significant frequencies across parts of the Arabian Peninsula and Yemen. In individuals of European ancestry, it is virtually absent (less than 0.1%).
No. The Duffy-null phenotype does not cause anemia, fatigue, weakness, or impaired oxygen carrying capacity. Red blood cell survival, hemoglobin levels, and platelet counts are completely normal. If an individual experiences unexplained fatigue, standard workup for iron deficiency, thyroid dysfunction, or vitamin B12 deficiency should be performed.
Over 99% of Duffy-null individuals carry the erythroid-specific GATA promoter variant (-46T>C), which preserves endothelial Duffy expression and confers natural immune tolerance to the Fy3 antigen, typically preventing the formation of anti-Fy3 antibodies. However, Duffy-null individuals lack the Fyª antigen and can form anti-Fyª antibodies if exposed to Fyª-positive blood. For single emergency transfusions, blood banks perform standard cross-matching. For patients requiring chronic transfusions (such as sickle cell disease), extended prophylactic matching is essential to prevent alloimmunization and delayed hemolytic transfusion reactions.
DuffyNull.com is an independent digital health education platform and voluntary registry project dedicated to translating peer-reviewed hematology literature (ASH DANC Initiative, Blood, JAMA) into accessible diagnostic stewardship tools, clinical calculators, and patient advocacy.
We operate as an open health science initiative committed to eradicating unnecessary bone marrow biopsies and addressing structural inclusion barriers in clinical research. We do not provide individualized medical diagnoses or direct healthcare services. All clinical algorithms strictly reflect published peer-reviewed medical literature.